Vera Therapeutics, Inc. stock is up 19.81% since 30 days ago. The next earnings date is Mar 26, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November. In the last 2 Unusual Options Trades, there were 1 PUT, 1 CALL. 100% of analysts rate it a buy.
Vera Therapeutics, Inc. focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for immunoglobulin A nephropathy.